抗体-药物偶联物
精密医学
结合
细胞外小泡
乳腺癌
计算生物学
个性化医疗
药物开发
医学
药品
计算机科学
药物发现
靶向治疗
癌症治疗
连接器
靶向给药
系统药理学
有效载荷(计算)
风险分析(工程)
生物信息学
癌症
癌症治疗
抗癌药
纳米载体
癌症研究
三阴性乳腺癌
纳米技术
药物输送
药理学
临床实习
精确肿瘤学
作者
Hussein Sabit,Salma Abbas,Moataz T. El-Safoury,Engy M. Madkour,Sahar Mahmoud,Shaimaa E. Abdel-Ghany,Yasser Albrahim,Ibtesam S. Al-Dhuayan,Sanaa Rashwan,Ahmed H. K. El-Hashash,Borros Arneth
出处
期刊:Biomedicines
[Multidisciplinary Digital Publishing Institute]
日期:2025-09-10
卷期号:13 (9): 2227-2227
被引量:16
标识
DOI:10.3390/biomedicines13092227
摘要
Antibody-drug conjugates (ADCs) have revolutionized breast cancer (BC) therapy by combining targeted antibody specificity with potent cytotoxic payloads, thereby enhancing efficacy while minimizing systemic toxicity. This review highlights significant innovations driving ADC development alongside persistent challenges. Recent advancements include novel antibody-drug conjugate (ADC) designs targeting diverse antigens, such as HER2, HER3, and CD276, demonstrating potent anti-tumor activity and improved strategies for drug delivery. For instance, dual-payload ADCs and those leveraging extracellular vesicles offer new dimensions in precision oncology. The integration of ADCs into sequential therapy, such as sacituzumab govitecan with TOP1/PARP inhibitors, further underscores their synergistic potential. Despite these innovations, critical challenges remain, including tumor heterogeneity and acquired drug resistance, which often involve complex molecular alterations. Moreover, optimizing ADC components, including linker chemistry and payload characteristics, is essential for ensuring stability and minimizing off-target toxicity. The burgeoning role of artificial intelligence and machine learning is pivotal in accelerating the design of ADCs, target identification, and personalized patient stratification. This review aims to comprehensively explore the cutting-edge innovations and inherent challenges in ADC development for BC, providing a holistic perspective on their current impact and future trajectory.
科研通智能强力驱动
Strongly Powered by AbleSci AI